Akerley, Wallace

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 15,155

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021: Featured Updates to the NCCN Guidelines

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 948

Non–Small Cell Lung Cancer, Version 6.2015

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 478

Cancer misinformation and harmful information on Facebook and other social media: a brief report

Johnson, S. B., Parsons, M., Dorff, T., Moran, M. S., Ward, J. H., Cohen, S. A., Akerley, W., Bauman, J., Hubbard, J., Spratt, D. E., et al. (2022) · JNCI: Journal of the National Cancer Institute

Misinformation and Its ImpactsSocial Media in Health Education

Cited by 210

Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

Jimeno, A., Gupta, S., Sullivan, R., Do, K. T., Akerley, W. L., Wang, D., Teoh, D., Schalper, K., Zacharek, S. J., Sun, J., et al. (2020) · Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 41

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).

Gadgeel, S. M., Miao, J., Riess, J. W., Mack, P. C., Gerstner, G. J., Burns, T. F., Taj, A., Akerley, W. L., Dragnev, K. H., Moon, J., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 15